PF-Atlas › Clinical Trials › NCT02648048

A Study of Oral Vismodegib in Combination With Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis

Pirfenidone · Phase 1

Registry ID
NCT02648048
Phase
Phase 1
Status
Completed
Drug / intervention
Pirfenidone
Sponsor
Hoffmann-La Roche
Start
2016-01-15
Enrollment
21
Locations
15

About this trial

This is a single arm, multicenter, open-label, Phase 1b study to evaluate the safety and tolerability of vismodegib in combination with pirfenidone in participants with idiopathic pulmonary fibrosis (IPF) currently being treated with pirfenidone.

View NCT02648048 on ClinicalTrials.gov →

Explore related

All Pirfenidone trialsAll IPF trials

Related trials

Pirfenidone — NCT00001959pirfenidone — NCT00662038Pirfenidone — NCT02951429Pirfenidone — NCT00287729Pirfenidone — NCT01504334Pirfenidone — NCT02932566
Medical disclaimer. This page summarizes public trial data for NCT02648048 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.